Revolution Medicines Inc. has announced that Barbara Weber, M.D., will resign from its board of directors, effective immediately before the company's 2025 annual stockholders meeting on June 26. Dr. Weber's departure relates to the activation of a clinical study under the company's collaboration with Tango Therapeutics, Inc., and is not due to any disagreements with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.